– Reuters
SVB Leerink Maintains Outperform on Beam Therapeutics, Raises Price Target to $121
SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $116 to $121.
Related Posts
Eaton Corp: Q4 Earnings Insights
Eaton Corp (NYSE:ETN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.
Vigil Neuroscience Announces First Patient Dosed In The IGNITE Phase 2 Clinical Trial To Evaluate VGL101 In Patients With ALSP
Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company dosed
Canaccord Genuity Initiates Coverage On Toast with Buy Rating, Announces Price Target of $64
Canaccord Genuity analyst David Hynes initiates coverage on Toast (NYSE:TOST) with a Buy rating and announces Price Target of $64.